142 related articles for article (PubMed ID: 36216850)
1. Feasibility of ApoC1 serum levels as tumor biomarker in glioblastoma patients: a pilot study.
Hilbert M; Kuzman P; Mueller WC; Meixensberger J; Nestler U
Sci Rep; 2022 Oct; 12(1):16981. PubMed ID: 36216850
[TBL] [Abstract][Full Text] [Related]
2. The Mean ApoC1 Serum Level in Postoperative Samples from Neurosurgical Patients Is Lower than in Preoperative Samples and during Chemotherapy.
Hilbert M; Kuzman P; Mueller WC; Nestler U
Biology (Basel); 2022 Jul; 11(7):. PubMed ID: 36101402
[TBL] [Abstract][Full Text] [Related]
3. Assessment of ApoC1, LuzP6, C12orf75 and OCC-1 in cystic glioblastoma using MALDI-TOF mass spectrometry, immunohistochemistry and qRT-PCR.
Evangelou P; Groll M; Oppermann H; Gaunitz F; Eisenlöffel C; Müller W; Eschrich K; Schänzer A; Nestler U
Med Mol Morphol; 2019 Dec; 52(4):217-225. PubMed ID: 31006040
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein C1 (APOC1), A Candidate Diagnostic Serum Biomarker for Breast Cancer Identified by Serum Proteomics Study.
Yan Y; Zhou Y; Wang K; Qiao Y; Zhao L; Chen M
Crit Rev Eukaryot Gene Expr; 2022; 32(4):1-9. PubMed ID: 35695660
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of Apolipoprotein C1 (APOC1) in Clear Cell Renal Cell Carcinoma and Its Prognostic Significance.
Xiao H; Xu Y
Med Sci Monit; 2021 Feb; 27():e929347. PubMed ID: 33591959
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for gastric cancer.
Yi J; Ren L; Wu J; Li W; Zheng X; Du G; Wang J
Ann Transl Med; 2019 Aug; 7(16):380. PubMed ID: 31555694
[TBL] [Abstract][Full Text] [Related]
7. Plasma apolipoprotein C1 concentration is associated with plasma triglyceride concentration, but not visceral fat, in patients with type 2 diabetes.
Bouillet B; Gautier T; Aho LS; Duvillard L; Petit JM; Lagrost L; Vergès B
Diabetes Metab; 2016 Sep; 42(4):263-6. PubMed ID: 26934823
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for lung cancer: A marker phase I trial.
Ko HL; Wang YS; Fong WL; Chi MS; Chi KH; Kao SJ
Thorac Cancer; 2014 Nov; 5(6):500-8. PubMed ID: 26767044
[TBL] [Abstract][Full Text] [Related]
9. The Apolipoprotein C1 is involved in breast cancer progression via EMT and MAPK/JNK pathway.
Zhang H; Wang Y; Liu C; Li W; Zhou F; Wang X; Zheng J
Pathol Res Pract; 2022 Jan; 229():153746. PubMed ID: 34952429
[TBL] [Abstract][Full Text] [Related]
10. Expression of apolipoprotein C1 in clear cell renal cell carcinoma: An oncogenic gene and a prognostic marker.
Wang HJ; Ma YX; Wang AH; Jiang YS; Jiang XZ
Kaohsiung J Med Sci; 2021 May; 37(5):419-426. PubMed ID: 33305507
[TBL] [Abstract][Full Text] [Related]
11. Characterization of apolipoprotein C1 in hepatitis C virus infection and morphogenesis.
Zhang H; Qiao L; Luo G
Virology; 2018 Nov; 524():1-9. PubMed ID: 30130702
[TBL] [Abstract][Full Text] [Related]
12. Effects of apoC1 genotypes on the hormonal levels, metabolic profile and PAF-AH activity in Chinese women with polycystic ovary syndrome.
Zhang R; Liu Q; Liu H; Bai H; Zhang Y; Guan L; Fan P
Lipids Health Dis; 2018 Apr; 17(1):77. PubMed ID: 29636060
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein C1 (APOC1): A Novel Diagnostic and Prognostic Biomarker for Clear Cell Renal Cell Carcinoma.
Cui Y; Miao C; Hou C; Wang Z; Liu B
Front Oncol; 2020; 10():1436. PubMed ID: 32974161
[No Abstract] [Full Text] [Related]
14. Apolipoprotein C1 (APOC1) promotes tumor progression via MAPK signaling pathways in colorectal cancer.
Ren H; Chen Z; Yang L; Xiong W; Yang H; Xu K; Zhai E; Ding L; He Y; Song X
Cancer Manag Res; 2019; 11():4917-4930. PubMed ID: 31213910
[No Abstract] [Full Text] [Related]
15. Apolipoprotein CI knock-out mice display impaired memory functions.
Berbée JF; Vanmierlo T; Abildayeva K; Blokland A; Jansen PJ; Lütjohann D; Gautier T; Sijbrands E; Prickaerts J; Hadfoune M; Ramaekers FC; Kuipers F; Rensen PC; Mulder M
J Alzheimers Dis; 2011; 23(4):737-47. PubMed ID: 21157034
[TBL] [Abstract][Full Text] [Related]
16. Hyperlipidemia and cutaneous abnormalities in transgenic mice overexpressing human apolipoprotein C1.
Jong MC; Gijbels MJ; Dahlmans VE; Gorp PJ; Koopman SJ; Ponec M; Hofker MH; Havekes LM
J Clin Invest; 1998 Jan; 101(1):145-52. PubMed ID: 9421476
[TBL] [Abstract][Full Text] [Related]
17. Glycation of apolipoprotein C1 impairs its CETP inhibitory property: pathophysiological relevance in patients with type 1 and type 2 diabetes.
Bouillet B; Gautier T; Blache D; Pais de Barros JP; Duvillard L; Petit JM; Lagrost L; Vergès B
Diabetes Care; 2014 Apr; 37(4):1148-56. PubMed ID: 24574346
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of Apoe and Apoc1 by two consecutive rounds of gene targeting: effects on mRNA expression levels of gene cluster members.
van Ree JH; van den Broek WJ; van der Zee A; Dahlmans VE; Wieringa B; Frants RR; Havekes LM; Hofker MH
Hum Mol Genet; 1995 Aug; 4(8):1403-9. PubMed ID: 7581381
[TBL] [Abstract][Full Text] [Related]
19. Hyperlipidaemia is associated with increased insulin-mediated glucose metabolism, reduced fatty acid metabolism and normal blood pressure in transgenic mice overexpressing human apolipoprotein C1.
Koopmans SJ; Jong MC; Que I; Dahlmans VE; Pijl H; Radder JK; Frölich M; Havekes LM
Diabetologia; 2001 Apr; 44(4):437-43. PubMed ID: 11357474
[TBL] [Abstract][Full Text] [Related]
20. Reduced very-low-density lipoprotein fractional catabolic rate in apolipoprotein C1-deficient mice.
Jong MC; van Ree JH; Dahlmans VE; Frants RR; Hofker MH; Havekes LM
Biochem J; 1997 Jan; 321 ( Pt 2)(Pt 2):445-50. PubMed ID: 9020879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
